表紙
市場調査レポート

癌の遺伝子治療市場分析

Cancer Gene Therapy Market Analysis

発行 KuicK Research 商品コード 302591
出版日 ページ情報 英文 300 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=104.18円で換算しております。

ご注意: DRM (デジタル著作権管理システム) 付PDFになります。制限内容はお問合せください。
Multi-User License: 会社全体での使用権

Back to Top
癌の遺伝子治療市場分析 Cancer Gene Therapy Market Analysis
出版日: 2014年03月01日 ページ情報: 英文 300 Pages
概要

遺伝子治療市場は初期の研究段階から、様々な疾患の治療に向けて薬剤の臨床開発を行なう段階へと変換を遂げています。現在は遺伝子治療の主要な応用先は癌治療となっており、臨床研究全体の60%以上を占めています。これは癌治療には大きなアンメットニーズがあり、かつ同市場の規模が大きいためです。

当レポートでは、癌の遺伝子治療薬動向、遺伝子治療の癌治療への応用現状、課題、遺伝子治療市場の法規制シナリオ、治験動向とともに、参入する企業の競合環境をまとめ、概略下記の構成で取り上げております。

第1章 遺伝子治療のイントロダクション

  • 遺伝子治療の歴史
  • 遺伝子治療のベクトル

第2章 世界の遺伝子治療市場

  • 市場概要
  • 遺伝子治療における新興動向

第3章 遺伝子治療における癌治療の重要性

第4章 遺伝子治療の癌治療への応用の現状

  • 現在利用可能な癌治療
  • 癌の遺伝子治療へのアプローチ
  • 癌治療に用いられている遺伝子治療
  • 遺伝子をがん患者に挿入する方法

第5章 癌の遺伝子治療市場動向

  • 癌の遺伝子治療のための好ましいパラメーター
  • 癌患者への遺伝子治療の応用に関わる問題
  • 癌の遺伝子治療の臨床動向

第6章 法規制シナリオ

  • EU
  • 米国

第7章 相、国、標的適応別治験動向

  • 相不明
  • 研究
  • 前臨床
  • 第1、2相
  • 第2相
  • 第3相

第8章 上市済み癌の遺伝子治療薬剤

第9章 中止・中断されたパイプライン

  • 開発レポートなし
  • 中止
  • 中断

第10章 競合環境

  • Advantagene
  • BioCancell
  • Celgene
  • Cell Genesys
  • Epeius Biotechnologies
  • GenVec
  • Introgen Therapeutics
  • MultiVir
  • ZIOPHARM Oncology
  • Shenzhen SiBiono GeneTech

図表

目次

The gene therapy market has undergone series of transformation from the initial days of research to current clinical development of drugs for treatment of multiple diseases. The initial studies of gene therapy were conducted mostly on monogenetic diseases, but the focus of the researchers rapidly shifted towards the cancer. The increasing popularity of cancer therapeutics as a major interest for gene therapy applications led to it accounting for a dominant share of more than 60% in the overall number of clinical studies. The reasons for cancer to become a preferred area of application for gene therapy are the significant unmet medical needs in cancer therapy, coupled with the large size of its market. Additionally, the ethical acceptance of gene therapy as a therapeutic solution also contributed to the shift of focus from monogenetic diseases to cancer.

A major part of the cancer gene therapy products for are currently in preclinical and Phase II of clinical trials. There has been marginal success in developing completely curative therapeutic drugs. The gene therapy drugs which have been approved till date are Gendicine & Rexin-G. Gendicine, which is developed by Shenzhen SiBiono Gene Technologies Co., is currently marketed only in China and Rexin-G in Philippines.

Gene therapy offers a large window of opportunities for the treatment of multiple cancers. The therapy has been found to be able to deliver special tumor suppressor genes to an individual, which could prevent the growth of malignant tumors and also reduce the metastatic disease. . The major concentration is being given to the rare tumor types such as pancreatic cancer, and highly prevalent tumor types such as breast cancer and prostate cancer. With the prevalence of cancer rising significantly, the future drug pipelines of the companies are mostly focusing on gene therapy for cancer.

Cancer Gene Therapy Report Highlights & Findings:

  • Cancer Gene Therapy Drugs in Pipeline: More Than 60
  • Highest Number of Drugs in Preclinical Stage: 37
  • Suspended & Discontinued Cancer Gene Therapy Drug Pipeline: 100
  • Significance of Oncology Therapeutics in Gene Therapy
  • Current Applications of Gene Therapy to Cancer Treatment
  • Favorable Parameters for Cancer Gene Therapy
  • Issued Involved with Application of Gene Therapy in Cancer Patients
  • Regulatory Scenario for Gene Therapy Market
  • Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

Table of Contents

1. Introduction to Gene Therapy

  • 1.1. History of Gene Therapy
  • 1.2. Vectors of Gene Therapy

2. Global Gene Therapy Market

  • 2.1. Market Overview
  • 2.2. Emerging Trends in Gene Therapy

3. Significance of Cancer Therapeutics in Gene Therapy

4. Current Applications of Gene Therapy to Cancer Treatment

  • 4.1. Cancer Treatments Currently Available
  • 4.2. Approaches to Cancer Gene Therapy
  • 4.3. Gene Therapy Used in Cancer Treatment
  • 4.4. Methods of Inserting Genes into Cancer Patients

5. Cancer Gene Therapy Market Dynamics

  • 5.1. Favorable Parameters for Cancer Gene Therapy
  • 5.2. Issued Involved with Application of Gene Therapy in Cancer Patients
  • 5.3. Cancer Gene Therapy Clinical Insight

6. Regulatory Scenario for Gene Therapy Market

  • 6.1. EU
  • 6.2. US

7. Cancer Gene Therapy Drug Clinical Trial Insight by Phase, Country & Target Indications

  • 7.1. Unknown Phase
  • 7.2. Research
  • 7.3. Preclinical
  • 7.4. Phase I/II
  • 7.5. Phase II
  • 7.6. Phase III

8. Marketed Cancer Gene Therapy Drugs

9. Suspended & Discontinued Cancer Gene Therapy Drug Pipeline

  • 9.1. No Development Reported
  • 9.2. Discontinued
  • 9.3. Suspended

10. Competitive Landscape

  • 10.1. Advantagene
  • 10.2. BioCancell
  • 10.3. Celgene
  • 10.4. Cell Genesys
  • 10.5. Epeius Biotechnologies
  • 10.6. GenVec
  • 10.7. Introgen Therapeutics
  • 10.8. MultiVir
  • 10.9. ZIOPHARM Oncology
  • 10.10. Shenzhen SiBiono GeneTech

List of Figures

  • Figure 3-1: Gene Therapy by Indication
  • Figure 5-1: Favorable Parameters for Cancer Gene Therapy
  • Figure 5-2: Cancer Gene Therapy Drug Clinical Pipeline by Phase (%), 2014
  • Figure 5-3: Cancer Gene Therapy Drug Clinical Pipeline by Phase (Number of Drugs), 2014
  • Figure 5-4: Suspended Cancer Gene Therapy Drug by Phase (%), 2014
  • Figure 5-5: Suspended Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
  • Figure 5-6: Discontinued Cancer Gene Therapy Drug by Phase (%), 2014
  • Figure 5-7: Discontinued Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
  • Figure 5-8: No Development Reported Cancer Gene Therapy Drug by Phase (%), 2014
  • Figure 5-9: No Development Reported Cancer Gene Therapy Drug by Phase (Number of Drugs), 2014
Back to Top